SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-18-176956
Filing Date
2018-05-29
Accepted
2018-05-29 17:18:56
Documents
9
Period of Report
2018-05-23
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d593903d8k.htm 8-K 24749
2 EX-1.1 d593903dex11.htm EX-1.1 180354
3 EX-5.1 d593903dex51.htm EX-5.1 7526
4 EX-99.1 d593903dex991.htm EX-99.1 15334
5 EX-99.2 d593903dex992.htm EX-99.2 13507
6 EX-99.3 d593903dex993.htm EX-99.3 13550
7 GRAPHIC g593903g0521133710881.jpg GRAPHIC 3633
8 GRAPHIC g593903g0524101039417.jpg GRAPHIC 3633
9 GRAPHIC g593903g0529135023199.jpg GRAPHIC 3633
  Complete submission text file 0001193125-18-176956.txt   271871
Mailing Address 300 GEORGE STREET SUITE 301 NEW HAVEN CT 06511
Business Address 300 GEORGE STREET SUITE 301 NEW HAVEN CT 06511 312 767 0291
MELINTA THERAPEUTICS, INC. /NEW/ (Filer) CIK: 0001461993 (see all company filings)

IRS No.: 454440364 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35405 | Film No.: 18865563
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences